nextcure.com (NXTC) - Debt to Equity

The price history of NextCure, Inc. (NXTC) demonstrates a total debt-to-equity ratio of 0.36. The company's quotes are minimally dependent on macroeconomics, as demand for oncology drugs remains stable. The business relies on expanding its antibody portfolio via the FIND IT system to identify partners. However, the current research stage does not provide economies of scale, triggering a proportional increase in R&D expenses.

This ratio determines the proportion of borrowed funds to equity assets, allowing for an assessment of financial autonomy and the risk of excessive corporate leverage. By analyzing the debt-to-equity level, an investor can judge the ability of NextCure, Inc. (NXTC) to ensure continuous funding for R&D projects and retain leading immunologists through a stable capital structure within the context of its scientific activities.